Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
New England Journal of Medicine2021Vol. 385(19), pp. 1774–1785
Citations Over TimeTop 1% of 2021 papers
Hana M. El Sahly, Lindsey R. Baden, Brandon Essink, Susanne Doblecki‐Lewis, Judith M. Martin, Evan J. Anderson, Thomas Campbell, Jesse L. Clark, Lisa A. Jackson, Carl J. Fichtenbaum, Marcus Zervos, Bruce Rankin, Frank Eder, Gregory Feldman, C Kennelly, Laurie J. Han-Conrad, Michael Levin, Kathleen M. Neuzil, Lawrence Corey, Peter B. Gilbert, Holly Janes, Dean Follmann, Mary Marovich, Laura Polakowski, John R. Mascola, Julie E. Ledgerwood, Barney S. Graham, Allison August, Heather Clouting, Weiping Deng, Shu Han, Brett Leav, Deb Manzo, Rolando Pajón, F. Schödel, Joanne E. Tomassini, Haiyu Zhou, Jacqueline M. Miller
Abstract
The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Related Papers
- → Strategies for Including Patients Recruited During Interim Analysis of Clinical Trials(2007)13 cited
- Policies for interim analysis and interim reporting of results.(1985)
- Selecting an interim analysis procedure.(1993)
- THE STUDY OF MULTI-ARMED INTERIM ANALYSIS IN CLINCAL TRIALS.(2004)
- Policies for Interim Analysis and Interim Reporting of Results(1985)